Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Advances in structure-based drug design of novel bacterial topoisomerase inhibitors.

Widdowson K, Hennessy A.

Future Med Chem. 2010 Nov;2(11):1619-22. doi: 10.4155/fmc.10.250. No abstract available.

2.

New inhibitors of bacterial topoisomerase GyrA/ParC subunits.

Black MT, Coleman K.

Curr Opin Investig Drugs. 2009 Aug;10(8):804-10. Review.

PMID:
19649925
3.

Topoisomerase inhibition, nucleolytic and electrolytic contribution on DNA binding activity exerted by biological active analogue of coordination compounds.

Patel MN, Bhatt BS, Dosi PA.

Appl Biochem Biotechnol. 2012 Apr;166(8):1949-68. doi: 10.1007/s12010-012-9623-x. Epub 2012 Mar 7.

PMID:
22391694
4.

Structures of kibdelomycin bound to Staphylococcus aureus GyrB and ParE showed a novel U-shaped binding mode.

Lu J, Patel S, Sharma N, Soisson SM, Kishii R, Takei M, Fukuda Y, Lumb KJ, Singh SB.

ACS Chem Biol. 2014 Sep 19;9(9):2023-31. doi: 10.1021/cb5001197. Epub 2014 Jul 3.

PMID:
24992706
5.

Molecular interactions of the CcdB poison with its bacterial target, the DNA gyrase.

Van Melderen L.

Int J Med Microbiol. 2002 Feb;291(6-7):537-44. Review.

PMID:
11890555
7.

Novel symmetric and asymmetric DNA scission determinants for Streptococcus pneumoniae topoisomerase IV and gyrase are clustered at the DNA breakage site.

Leo E, Gould KA, Pan XS, Capranico G, Sanderson MR, Palumbo M, Fisher LM.

J Biol Chem. 2005 Apr 8;280(14):14252-63. Epub 2005 Jan 18.

8.

Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents.

Oblak M, Kotnik M, Solmajer T.

Curr Med Chem. 2007;14(19):2033-47. Review.

PMID:
17691945
9.

De novo design of novel DNA-gyrase inhibitors based on 2D molecular fingerprints.

Huang Z, Lin K, You Q.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4166-71. doi: 10.1016/j.bmcl.2013.05.033. Epub 2013 May 18.

PMID:
23743285
10.

The role of enzymology in a structure-based drug discovery program: bacterial DNA gyrase.

Cunningham ML.

Methods Mol Biol. 2012;841:179-207. doi: 10.1007/978-1-61779-520-6_8.

PMID:
22222453
11.

Evolutionary twist on topoisomerases: conversion of gyrase to topoisomerase IV.

Neuman KC.

Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22363-4. doi: 10.1073/pnas.1016041108. Epub 2010 Dec 17. No abstract available.

12.

Development and use of a high-throughput bacterial DNA gyrase assay to identify mammalian topoisomerase II inhibitors with whole-cell anticancer activity.

Roychoudhury S, Makin KM, Twinem TL, Stanton DT, Nelson SL, Catrenich CE.

J Biomol Screen. 2003 Apr;8(2):157-63.

PMID:
12844436
13.

Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.

Charifson PS, Grillot AL, Grossman TH, Parsons JD, Badia M, Bellon S, Deininger DD, Drumm JE, Gross CH, LeTiran A, Liao Y, Mani N, Nicolau DP, Perola E, Ronkin S, Shannon D, Swenson LL, Tang Q, Tessier PR, Tian SK, Trudeau M, Wang T, Wei Y, Zhang H, Stamos D.

J Med Chem. 2008 Sep 11;51(17):5243-63. doi: 10.1021/jm800318d. Epub 2008 Aug 9.

PMID:
18690678
14.

Mechanism of binding of fluoroquinolones to the quinolone resistance-determining region of DNA gyrase: towards an understanding of the molecular basis of quinolone resistance.

Madurga S, Sánchez-Céspedes J, Belda I, Vila J, Giralt E.

Chembiochem. 2008 Sep 1;9(13):2081-6. doi: 10.1002/cbic.200800041.

PMID:
18677735
15.

The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action.

Heddle JG, Barnard FM, Wentzell LM, Maxwell A.

Nucleosides Nucleotides Nucleic Acids. 2000 Aug;19(8):1249-64. Review.

PMID:
11097055
16.

The RuvAB branch migration complex can displace topoisomerase IV.quinolone.DNA ternary complexes.

Shea ME, Hiasa H.

J Biol Chem. 2003 Nov 28;278(48):48485-90. Epub 2003 Sep 17.

17.

Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids.

Hubschwerlen C, Specklin JL, Sigwalt C, Schroeder S, Locher HH.

Bioorg Med Chem. 2003 May 15;11(10):2313-9.

PMID:
12713843
18.

YacG from Escherichia coli is a specific endogenous inhibitor of DNA gyrase.

Sengupta S, Nagaraja V.

Nucleic Acids Res. 2008 Aug;36(13):4310-6. doi: 10.1093/nar/gkn355. Epub 2008 Jun 27.

19.

Synthesis, DNA-binding and topoisomerase inhibitory activity of ruthenium(II) polypyridyl complexes.

Du KJ, Wang JQ, Kou JF, Li GY, Wang LL, Chao H, Ji LN.

Eur J Med Chem. 2011 Apr;46(4):1056-65. doi: 10.1016/j.ejmech.2011.01.019. Epub 2011 Jan 21.

PMID:
21295892
20.

DNA topoisomerases: single gyrase caught in the act.

Bates AD.

Curr Biol. 2006 Mar 21;16(6):R204-6.

Supplemental Content

Support Center